other exon skipping candidates — IND submission
2026
Expect to submit multiple CTAs for other exon skipping candidates in 2026Source filing
WVE biotech catalysts & pipeline
WAVE LIFE SCIENCES LTD · Data as of 2026-09-08
Upcoming catalysts
WVE-008 — IND submission
2026
2026: File a Clinical Trial Application ("CTA") for WVE-008 Liver disease WVE-N531 (Exon 53)Source filing
WVE-N531 — NDA/BLA submission
in 2026
WVE-N531: Wave remains on track to file a New Drug Application (NDA) in 2026 to support accelerated approval of WVE-N531 with monthly dosing.Source filing
WVE-006 — Interim data
H2 2026
Wave expects to share data from the 600 mg (monthly) multidose cohort in the second half of 2026.Source filing
WVE-007 — Topline data
H2 2026
Additional data from the INLIGHT trial, including data from the 600 mg Phase 1 SAD cohort, are expected in the second half of 2026.Source filing
WVE-008 — IND submission
2H 2026
CTA submission for WVE-008 for PNPLA3 liver disease (GalNAc-RNA editing) on track for 2H 2026Source filing
WVE-006 — FDA meeting
Late 2026
FDA meeting scheduled for end of summer 2026 on potential accelerated approval pathway for WVE-006 (GalNAc-RNA editing); data from RestorAATion-2 trial support differentiated therapeutic approach for both lung and liver manifestations of AATDSource filing